{"url_path":"/sec/edsa/8-k/2026-05-15/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1540159/0001171843-26-003459-index.html","accession_number":"0001171843-26-003459","cik":"0001540159","ticker":"EDSA","issuer_name":"Edesa Biotech, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1540159/0001171843-26-003459-index.html","primary_entity_key":"0001540159","primary_entity_name":"Edesa Biotech, Inc."},"word_count":313,"has_tables":true,"body_markdown":"false\n0001540159\n\n0001540159\n\n2026-05-13\n2026-05-13\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n \n\n \n\n** **\n\n**FORM 8-K**\n\n \n\n \n\n** **\n\n**CURRENT REPORT**\n\n**PURSUANT TO SECTION 13 OR 15(d) OF**\n\n**THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n\n**Date of Report (Date of earliest event reported): May 13, 2026**\n\n \n\n**Edesa Biotech, Inc.**\n\n**(Exact Name of Registrant as Specified in its Charter)**\n\n \n\n**British Columbia, Canada**\n \n**001-37619**\n \n**N/A**\n\n(State or Other Jurisdiction\n\nof Incorporation)\n\n \n\n(Commission\n\nFile Number)\n\n \n\n(IRS Employer\n\nIdentification No.)\n\n \n \n\n**100 Spy Court, Markham, Ontario, Canada**\n** **\n**L3R 5H6**\n\n(Address of Principal Executive Offices)\n \n(Zip Code)\n\n \n \n \n \n \n \n \n\n \n\n**(289) 800-9600**\n\nRegistrant’s telephone number, including area code\n\n \n\n**N/A**\n\n(Former name or former address, if changed since last report)\n\n \n\nCheck the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy\nthe filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):\n\n \n\n☐ \nWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n \n\n☐ \nSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n \n\n☐ \nPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n \n\n☐ \nPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\n \n\nSecurities registered pursuant to Section 12(b) of the Act:\n\n** **\n\n**Title of each class**\n \n**Trading Symbol(s)**\n \n**Name of exchange on which registered**\n\nCommon Shares\n \nEDSA\n \nThe Nasdaq Stock Market LLC\n\n \n\nIndicate by check mark whether the registrant is an emerging growth company as defined in Rule\n405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2\nof this chapter). Emerging growth company ☐\n\n \n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use\nthe extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a)\nof the Exchange Act. ☐"}